中国生物制药四代EGFR抑制剂TQB3002获FDA临床试验许可

财中社
14 Nov 2024

财中社11月14日电中国生物制药(01177)发布自愿公告,宣布其自主研发的四代EGFR抑制剂TQB3002已获得美国食品药品监督管理局(FDA)的临床试验申请(IND)许可,即将启动I期临床试验。该药物旨在应对非小细胞肺癌中EGFR突变的耐药问题,具有较强的抑制活性和良好的耐受性。根据临床前研究,TQB3002能够有效抑制EGFR单突变和双突变的激酶活性,并在相关细胞系和动物模型中显示出剂量...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10